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Abstract
Background: High frequency chest wall oscillation (HFCWO) is used for airway mucus clearance. The objective of
this study was to evaluate the use of HFCWO early in the treatment of adults hospitalized for acute asthma or
chronic obstructive pulmonary disease (COPD).
Methods: Randomized, multi-center, double-masked phase II clinical trial of active or sham treatment initiated
within 24 hours of hospital admission for acute asthma or COPD at four academic medical centers. Patients
received active or sham treatment for 15 minutes three times a day for four treatments. Medical management was
standardized across groups. The primary outcomes were patient adherence to therapy after four treatments
(minutes used/60 minutes prescribed) and satisfaction. Secondary outcomes included change in Borg dyspnea
score (≥ 1 unit indicates a clinically significant change), spontaneously expectorated sputum volume, and forced
expired volume in 1 second.
Results: Fifty-two participants were randomized to active (n = 25) or sham (n = 27) treatment. Patient adherence
was similarly high in both groups (91% vs. 93%; p = 0.70). Patient satisfaction was also similarly high in both
groups. After four treatments, a higher proportion of patients in the active treatment group had a clinically
significant improvement in dyspnea (70.8% vs. 42.3%, p = 0.04). There were no significant differences in other
secondary outcomes.
Conclusions: HFCWO is well tolerated in adults hospitalized for acute asthma or COPD and significantly improves
dyspnea. The high levels of patient satisfaction in both treatment groups justify the need for sham controls when
evaluating the use of HFCWO on patient-reported outcomes. Additional studies are needed to more fully evaluate
the role of HFCWO in improving in-hospital and post-discharge outcomes in this population.
Trial Registration: ClinicalTrials.gov: NCT00181285
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A c u t ea s t h m aa n dc h r o n i co b s t r u c t i v ep u l m o n a r yd i s -
ease (COPD) are exceedingly common, which together
account for nearly 1 million hospitalizations each year
in the United States alone [1-6]. Beta agonists, anti-cho-
linergics, and corticosteroids delivered in aerosolized
forms (via respiratory inhalers or nebulization) are
recommended in the treatment of acute asthma and
COPD. These medications rely on deposition into distal
airspaces to suppress airway inflammation or promote
bronchodilation. Unfortunately, excessive mucous pro-
duction and impaired airway mucociliaryclearance can
lead to airway plugging, and thereby reduce the deposi-
tion of and response to aerosolized medications. These
considerations highlight the need for therapies that clear
airways of mucus in the acute management of asthma
and COPD [7-11].
High frequency chest wall oscillation (HFCWO) cre-
ates high velocity, low amplitude oscillatory airflows
when applied through a pneumatic vest worn over the
thorax, and is used for airway mucus clearance in
patients with cystic fibrosis, bronchiectasis, and neuro-
m u s c u l a rd i s o r d e r s[ 1 2 - 1 5 ] .S t u d i e si np a t i e n t sw i t h
cystic fibrosis suggest that HFCWO applied via a pneu-
matic vest is as effective as other modes of airway
mucus clearance, including hand-held devices (e.g., flut-
ter devices) and conventional chest physiotherapy[16].
HFCWO offers the advantage that it can be performed
in acutely ill patients who may be unable to use hand-
held devices effectively, such as early in the course of
hospitalization. Moreover, HFCWO can be performed
without the assistance from trained health care person-
nel, and may therefore offer a practical advantage com-
pared to chest physiotherapy. Pneumatic vests worn
over the chest, however, may not be acceptable to
patients with asthma or COPD with worsening respira-
tory symptoms. To our knowledge, no studies have
examined the use of HFCWO in the management of
acute asthma or COPD. The objective of this phase II
clinical trial (Chest Wall Oscillation for Asthma and
COPD ExacerbaTions [COAT] Trial) was therefore to
evaluate the use of HFCWO early in the treatment of
adults hospitalized for acute asthma or COPD. To mini-
mize the risk of bias, we included active and sham
HFCWO treatment groups and standardized medical
management in both treatment groups. Preliminary
results of this study were previously reported in the
form of an abstract [17].
Methods
Recruitment
Adults (age 18 years and older) admitted with a physi-
cian-diagnosis of acute asthma or COPD at one of four
academic medical centers were screened for this study.
The treating physician was contacted to confirm the
clinical diagnosis (acute asthma, acute COPD, or acute
asthma and COPD) and for verbal consent prior to
approaching patients for written informed consent. Inclu-
sion criteria included admission to the inpatient medical
service and evidence of airflow obstruction on spirometry
(forced expired volume in 1 second/forced vital capacity
[FEV1/FVC] < 70%) at the time of screening. Exclusion
criteria were: more than 24 hours since hospital admis-
sion, hospital discharge planned within 24 hours, admis-
sion to an intensive care unit, other chronic respiratory
diseases (e.g. sarcoidosis), chest wall abnormalities (e.g.
severe kyphoscoliosis), chest wall or abdominal trauma/
surgery in the past 6 weeks, systemic corticosteroid ther-
apy for 7 or more days prior to hospital admission, indi-
cation for systemic corticosteroids other than asthma or
COPD, patient unable (e.g. due to illness) or unwilling to
provide consent, and previous participation. Institutional
review boards at participating institutions approved this
study (University of Chicago, and Mercy Hospital and
Medical Center in Chicago, Illinois, U.S.A.; Johns
Hopkins Bayview Medical Center, and Johns Hopkins
Hospital, in Baltimore, Maryland, U.S.A.).
Baseline evaluation and randomization
Participants completed an interviewer-administered
questionnaire about demographics, acute care for
asthma or COPD in the past year (hospitalizations,
emergency room visits, and courses of systemic corticos-
teroids), and dyspnea using the modified Borg scale.
Spirometry (KoKo
®; Pulmonary Data Services Instru-
mentation; Louisville, CO) was performed after provid-
ing 2 puffs of albuterol via a metered dose inhaler
(MDI) and spacer to measure the post-bronchodilator
[post-BD] FEV1/FVC and post-BD FEV1 %p r e d i c t e d .
Participants were then randomized to active or sham
HFCWO, stratified by site and diagnosis using permuted
blocks to ensure balance across treatment groups.
Treatment conditions
Active HFCWO (The Vest
® Airway Clearance System,
Hill-Rom, Inc.; pressure dial settings 4-6 units and fre-
quency 10-12 Hz) consists of an inflatable vest and an
air-pulse generator, creating oscillatory chest wall com-
pressions and airflow[13,14]. The sham device had a
pressure bypass circuit, which provided a vibratory sen-
sation over the chest without causing airflow oscillation
and was indistinguishable from the active HFCWO
device in appearance and noise production. Treatments
were administered by research assistants over 15 min-
utes and delivered at 8 AM, 12 Noon, and 4 PM each
day after 4 puffs of albuterol MDI, 90 mcg/puff. Each
participant was prescribed four treatments (total
of 60 minutes). Treatments could be interrupted or
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participant. Research assistants who helped participants
put on and activate the pneumatic vest were not
involved in the collection of baseline data or outcomes.
Also, treating physicians were not permitted to observe
study treatments to avoid changes in care due to
unmasking.
Based on national asthma [18] and COPD [19] guide-
lines, medical management was standardized for all par-
ticipants. Participants received aerosolized albuterol
every 4 hours and every 1-2 hours as needed (2.5 mg/
mL via nebulization or 90 mcg/puff via MDI, 4 puffs, at
the discretion of treating physicians), systemic corticos-
teroids daily (prednisone 60 mg by mouth or equivalent
intravenous dose of methylprednisolone [48 mg], at the
discretion of treating physician), inhaled corticosteroids/
long-acting bronchodilator (fluticasone/salmeterol 250
mcg/50 mcg via Diskus
®) one inhalation twice daily,
and supplemental oxygen to keep saturations above
93%. Other medications could be prescribed at the dis-
cretion of the treating physician.
Evaluation after four treatments
We assessed patient adherence to prescribed study treat-
ments (minutes used/60 minutes prescribed) and patient
satisfaction with study treatment. Satisfaction items
were developed for the study and intended to provide
descriptive information rather than serve as an efficacy
endpoint so formal methodologies typically used to
develop and validate patient-reported outcomes (e.g.,
item generation, item reduction) were not employed.
The satisfaction items were: 1) The study vest was con-
venient to use; 2) The study vest was easy to use; 3)
The study vest was comfortable; 4) The study vest
helped me feel better; 5) The study vest helped me
breathe better; 6) I felt safe using the study vest; 7) I
would recommend the study vest to someone with my
type of breathing problem; 8) I want my doctor to pre-
scribe the study vest for me. Participants were asked to
use a 5-point scale (strongly agree, somewhat agree,
neither agree nor disagree, somewhat disagree, strongly
disagree) when rating their satisfaction:
The modified Borg scale was used to collect data
about dyspnea after four treatments; a ≥ 1u n i tr e d u c -
tion defines a clinically meaningful change[20]. Sponta-
neously expectorated sputum volume (wet volume) after
four treatments was measured. Participants were
instructed to expectorate as needed into a study con-
tainer provided at the baseline visit, which was collected
after the fourth treatment. Spirometry was used to mea-
sure post-BD FEV1 % predicted 15-30 minutes after
2 puffs of albuterol MDI.
Decisions regarding hospital discharge were at the dis-
cretion of the treating physicians. Discharge medications
were standardized to include prednisone 50 mg daily to
complete a 10-day course of systemic corticosteroids,
inhaled fluticasone/salmeterol 250 mcg/50 mcg Diskus 1
inhalation twice daily, and inhaled albuterol MDI with
spacer 2 puffs every four hours as needed. At a follow-
up study visit conducted by telephone, patient-reported
respiratory-related acute care at 30 days (additional
course of systemic corticosteroids, emergency depart-
ment visit, or hospitalization for “difficulty breathing,
cough, or chest tightness”) was assessed.
Statistical Analysis
The co-primary outcomes were patient adherence and
satisfaction with HFCWO immediately after four study
treatments. Responses to each satisfaction item were
collapsed into agree (’yes’ [strongly or somewhat agree]
or ‘no’ [else]). Secondary outcomes after four study
treatments were the change in dyspnea (follow-up -
baseline Borg score), the proportion with a clinically
meaningful change in dyspnea, volume of expectorated
sputum, and change in post-bronchodilator FEV1%p r e -
dicted (follow-up - baseline). Length of hospital stay
after study treatment and respiratory-related acute care
within 30 days of discharge were other secondary out-
comes. Wilcoxon ranksum tests, or Chi
2 tests were per-
formed, as appropriate, for comparisons between
groups. A two-tailed p-value less than 0.05 defined sta-
tistical significance. This was a Phase II clinical trial pri-
marily designed to assess patient adherence and
satisfaction regarding the early use of HFCWO during
acute asthma and COPD, so no formal sample size cal-
culations were performed. Results of this study were
intended to provide the information needed for sample
size calculations for subsequent studies. Version 9.2 of
the SAS System (SAS Institute Inc., Cary, NC) was used
for all analyses.
Results
Of the 94 patients who met inclusion criteria, 42 (45%)
met exclusion criteria (Figure 1). The most common
reasons for exclusion were inability to obtain patient
consent (e.g., patients were acutely ill and unable to pro-
vide written informed consent or patients declined parti-
cipation, n = 17), chest wall or abdominal surgery or
trauma in the past six weeks (n = 11), and hospital dis-
charge planned within 24 hours (n = 3). Fifty-two
patients (55% of those who met inclusion criteria) were
randomized to receive either active HFCWO (n = 25) or
sham HFCWO (n = 27). Nearly two-thirds of study par-
ticipants had acute asthma. Participants had, on average,
one other hospitalization and two previous courses of
systemic corticosteroids in the past year. Baseline char-
acteristics were similar in the two treatment groups
(Table 1).
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Patient adherence to active and to sham HFCWO was
similarly high (91% vs. 93%, p = 0.70) in both groups.
Satisfaction with study treatment was also high, even in
the sham HFCWO group (active vs. sham HFCWO:
comfortable, 88% vs. 92%, p = 0.67; feel better, 80% vs.
85%, p = 0.73).
Secondary Outcomes (Table 3)
After four treatments, there was significantly greater
improvement in dyspnea in the active HFCWO group
(median change in Borg score of -1.5 vs. 0 units, p =
0.048). Nearly twice as many patients reported a clini-
cally meaningful improvement in dyspnea in the active
HFCWO group than in the sham HFCWO group (71%
vs. 42%, p = 0.04). There were no significant differences
in other secondary outcomes. Five participants (2 in the
active group, 3 in the sham group) did not complete the
30 day follow-up visit. Among those with evaluable data,
approximately 20% had a respiratory-related acute care
event at 30 days and were similar in frequency in the
two treatment groups.
Discussion
In this multi-center phase II clinical trial, we found that
HFCWO initiated within 24 hours of hospital admission
for acute asthma or COPD is associated with high levels
of patient adherence and satisfaction. In addition,
HFCWO significantly improved dyspnea compared to
sham HFCWO, but there were no other significant dif-
ferences in secondary outcomes between treatment
groups.
Figure 1 Flowchart of Study Cohort. N = 94 adults (age 18 years
and older) admitted with a physician-diagnosis of acute asthma or
COPD and with FEV1/FVC < 70% at the time of screening were
assessed for eligibility. Fifty-two (55%) were randomized to active
HFCWO (n = 25) or sham HFCWO (n = 27).
Table 1 Baseline characteristics of study participants
Characteristic Active HFCWO
(n = 25)
Sham HFCWO
(n = 27)
p-value
Diagnosis, n (%) Acute asthma 15 (60) 16 (59) > 0.99
Acute COPD 9 (36) 10 (37)
Acute asthma and COPD 1 (4) 1 (4)
Age, years 46.5 [38.6, 52.8] 50.4 [43.9, 60.7] 0.28
BMI, kg/m
2 27.0 [23.7, 33.0] 29.7 [23.7, 38.0] 0.43
Post-BD FEV1% predicted 45 [26, 58]
n=2 3
40 [33, 55]
n=2 5
0.75
Post-BD FEV1/FVC, % 61 [49, 66]
n=2 3
55 [49, 66]
n=2 5
0.55
Hospitalizations past year (excluding current) 1 [0, 3]
n=2 1
1 [0, 4]
n=2 1
0.98
Emergency room visits past year 2 [0, 4] 4 [0, 5]
n=2 5
0.50
Corticosteroid courses past year 2 [0, 4]
n=2 4
2 [0, 5]
n=2 5
0.58
The median [interquartile range] is reported, unless otherwise stated. The number (n) of participants with data is included in the table, if n is less than the
number of participants assigned to each treatment group. Missing data were due to difficulty in performing some tests in acutely ill patients (e.g., post-BD
spirometry) or non-response (e.g., problems with patient recall). HFCWO = high frequency chest wall oscillation, BMI = body mass index, Post-BD FEV1= post-
bronchodilator forced expiratory volume in 1 second, Post-BD FEV1/FVC = post-bronchodilator forced expiratory volume in once second/forced vital capacity.
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in this phase II study establishes the feasibility of
HFCWO in this population. Study coordinators assisted
patients in the use and activation of pneumatic vests, so
it is possible that the high rates of adherence would not
occur without such assistance. Without the sham
HFCWO control group, we may have erroneously con-
cluded that HFCWO increased patient satisfaction com-
pared to standard medical management alone. Our
findings justify the need for sham controls when testing
the effect of airway clearance devices on patient-
reported outcomes [21].
Nearly twice as many patients treated with active
HFCWO reported a clinically significant improvement
in dyspnea than with sham HFCWO (71% vs. 42%),
which translates into a number needed to treat of
approximately 3 (i.e., for every 3 patients treated with
active HFCWO, 1 additional patient would report an
improvement in dyspnea). These results are unlikely to
be explained by reporting bias by the participant or bias
in data collection by the research staff, since we
employed a sham control group and the study staff who
helped participants put on and activate the pneumatic
vest were not involved in the collection of outcome data
W h i l ew ed i ds t a n d a r d i z em u l t i p l ea s p e c t so fm e d i c a l
management of acute asthma or COPD, we did not col-
lect data on the use of co-therapies (e.g., use of anti-
cholinergic bronchodilators, use of antibiotics), so can-
not exclude the possibility that differences in co-thera-
pies contributed to observed differences in dyspnea.
However, we believe the likelihood of differences in co-
therapies between groups is low, as treating physicians
were not permitted to observe the study treatments.
We did not find differences in other secondary out-
comes between treatment groups, including those that
may be expected to improve with greater airway clear-
ance, such as expectorated sputum volume or airflow
obstruction. There are three possible explanations. First,
this study may have been underpowered or have had
insufficient treatment duration to detect improvements
in these other outcomes. Second, we may not have mea-
sured markers of airway clearance with adequate preci-
sion. Use of spontaneously expectorated sputum volume
as an outcome can be problematic due to variability in
Table 2 Primary outcomes: adherence to treatment and
patient satisfaction
Active HFCWO
(n = 25)
Sham HFCWO
(n = 27)
p-value
Adherence, mean (SD) 91% (21.1%) 93% (18.7%) 0.70
Satisfaction
Convenient 79%
n=2 4
92%
n=2 6
0.24
Easy to use 92% 92%
n=2 6
> 0.99
Comfortable 88% 92%
n=2 6
0.67
Helped me feel
better
80% 85%
n=2 6
0.73
Helped me breathe 84% 69%
n=2 6
0.32
Felt safe 100% 96%
n=2 6
> 0.99
Would recommend
to someone
92% 85%
n=2 6
0.67
Want my doctor to
prescribe
76% 81%
n=2 6
0.74
One participant in the active HFCWO group had missing data for 1 of the
patient satisfaction items. One participant in the sham HFCWO group had
missing data for all the satisfaction items.
Table 3 Secondary outcomes
Active HFCWO (n = 25) Sham HFCWO (n = 27) Comparison between groups p-value
After four treatments
Change in Borg score -1.5 [-3.5, 0]
n=2 4
0 [-2, 0]
n=2 6
0.048
Expectorated sputum, mL 10 [8, 20] 11 [6, 45] 0.44
Change in post-BD FEV1%
predicted
0 [-2, 8]
n=2 2
2 [-3, 9]
n=2 3
0.69
Length of hospital stay, days 2 [1, 3] 2 [1, 4] 0.75
Respiratory- related acute care at 30 days
Systemic corticosteroids, n (%) 4 (17)
n=2 3
2 (8)
n=2 4
0.42
Acute care visit (hospitalization or
ED visit), n (%)
4 (17)
n=2 3
4 (17)
n=2 4
> 0.99
Either 5 (22)
n=2 3
4 (17)
n=2 4
0.72
The median [interquartile range] is reported, unless otherwise stated. The number (n) of participants with data is included in the table, if n is less than the
number of participants assigned to each treatment group. Missing data were due to difficulty in performing some tests in acutely ill patients (e.g., post-BD
spirometry) or non-response (e.g., problems with patient recall or inability to respond). There were five participants lost to follow-up (2 in active HFCWO, 3 in
sham HFCWO groups).
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It is also possible that participants may have swallowed
sputum or expectorated sputum into containers other
than those provided by the research staff. The design of
future studies of airway clearance may need to include
procedures to assure collection of spontaneously expec-
torated sputum, to actively encourage cough during and
after HFCWO, and to measure wet or dry sputum
weight (which may help overcome the effects of dry
hospital air on sputum volume). Also, lung volumes and
impulse oscillometry may have provided a more sensi-
tive measure of airway clearance[22]. Third, the
improvement in dyspnea with HFCWO may have been
a type I error.
Nevertheless, results of our study are encouraging and
can be used to inform the design of larger-scale, more
definitive trials testing the efficacy of HFCWO on clini-
cal endpoints (e.g., feasibility of using HFCWO for acute
asthma or COPD, need for a sham-control, need for
additional measures of airway clearance). The most
common reason for exclusion was the inability to obtain
written informed consent from patients. We suspect
that patients were concerned about using a pneumatic
vest over their chest in a research study during an acute
respiratory event. The patient adherence and satisfaction
data from this study should be reassuring and may help
to facilitate enrollment in future studies. We found that
about 1 in 5 patients required acute care for worsening
respiratory symptoms within 30 days of hospital dis-
charge; the prevalence of acute care was similar between
treatment groups. We employed a limited treatment
period (4 treatments spanning 2 calendar days) and
found that HFCWO significantly improves dyspnea over
this treatment period. Studies using a longer treatment
period (e.g., through 30 days post-discharge) are needed
to determine if HFCWO improves other clinically mean-
ingful outcomes during the hospitalization (e.g., hospital
length of stay), the need for acute care post-discharge,
and other outcomes (e.g., local and systemic markers of
inflammation, six minute walk distance). Additional, lar-
ger studies are also needed to determine which specific
patient subgroups (e.g., acute asthma vs. acute COPD;
evidence of airway mucus plugging on chest imaging,
yes vs. no) are most likely to benefit from HFCWO.
Conclusions
HFCWO is well tolerated when added to standard medi-
cal management in adults hospitalized with acute
asthma or COPD and has a large beneficial effect on
dyspnea (a number needed to treat of about 3) com-
pared to sham treatment. The high levels of patient
satisfaction, including in the sham group, justify the
need for sham controls when testing the effect of
HFCWO on patient-reported outcomes. Larger studies
with a longer treatment period are needed to more fully
evaluate the role of HFCWO in improving in-hospital
and post-discharge outcomes in this population.
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